Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years

Objective: To assess the management and oncological outcomes in men diagnosed with Gleason score (GS) 6 prostate cancer on needle biopsy in a regional centre, as compared with published international data. Materials and methods: A retrospective analysis was conducted of patients who were diagnosed w...

Full description

Bibliographic Details
Main Authors: Brayden March, George Koufogiannis, Mark Louie-Johnsun
Format: Article
Language:English
Published: Elsevier 2017-12-01
Series:Prostate International
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S228788821730020X
_version_ 1797766313144221696
author Brayden March
George Koufogiannis
Mark Louie-Johnsun
author_facet Brayden March
George Koufogiannis
Mark Louie-Johnsun
author_sort Brayden March
collection DOAJ
description Objective: To assess the management and oncological outcomes in men diagnosed with Gleason score (GS) 6 prostate cancer on needle biopsy in a regional centre, as compared with published international data. Materials and methods: A retrospective analysis was conducted of patients who were diagnosed with GS 6 prostate cancer via transrectal ultrasound-guided or transperineal biopsy between June 2009 and September 2015 under the care of a single surgeon. Data were obtained from a prospectively collected database. Results: A total of 166 patients were diagnosed with GS 6 prostate cancer. The mean age was 61 (range 46–79) years, with mean prostate-specific antigen of 6.7 (0.91–26.8) ng/mL at diagnosis. Of 166 patients, 117 (70.5%) patients were enrolled into the active surveillance program with 82 (70%) meeting Prostate Cancer Research International Active Surveillance (PRIAS) criteria, 44 patients underwent immediate definitive treatment (88.6% radical prostatectomy and 9.1% radiotherapy) and five watchful waiting. With a median follow-up of 1.8 years, 37 (31.6%) patients on AS had definitive treatment [30 cases (81%) were attributable to disease progression, 4 cases (10.8%) to an abnormal magnetic resonance imaging result and 3 cases (8.1%) for patient preference]. In the 35 patients who underwent radical prostatectomy immediately after diagnosis, the GS was ≥7 in 29 cases (82.9%), and the final pathology was pT3a in 16 (51.6%) and pT3b in one (2.9%). In patients who underwent radical prostatectomy after being on AS, the proportion of GS ≥7 prostate cancer was 29/32 (90.6%), with pT3a in six (18.8%) and pT3b in three (9.4%) cases. Overall, 23.5% of patients had a multiparametric magnetic resonance imaging scan. Conclusion: This single-surgeon cohort of GS 6 prostate cancer patients demonstrates a high proportion of cases managed with active surveillance, with comparable rates to international literature. The majority of cases who underwent immediate definitive treatment had significant disease, indicating that patients are being appropriately selected for active surveillance.
first_indexed 2024-03-12T20:22:29Z
format Article
id doaj.art-71311a3d28d5450d917f550b0e0d701d
institution Directory Open Access Journal
issn 2287-8882
language English
last_indexed 2024-03-12T20:22:29Z
publishDate 2017-12-01
publisher Elsevier
record_format Article
series Prostate International
spelling doaj.art-71311a3d28d5450d917f550b0e0d701d2023-08-02T00:47:29ZengElsevierProstate International2287-88822017-12-015413914210.1016/j.prnil.2017.03.007Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 yearsBrayden March0George Koufogiannis1Mark Louie-Johnsun2Gosford Hospital, Gosford, NSW, AustraliaGosford Hospital, Gosford, NSW, AustraliaGosford Hospital, Gosford, NSW, AustraliaObjective: To assess the management and oncological outcomes in men diagnosed with Gleason score (GS) 6 prostate cancer on needle biopsy in a regional centre, as compared with published international data. Materials and methods: A retrospective analysis was conducted of patients who were diagnosed with GS 6 prostate cancer via transrectal ultrasound-guided or transperineal biopsy between June 2009 and September 2015 under the care of a single surgeon. Data were obtained from a prospectively collected database. Results: A total of 166 patients were diagnosed with GS 6 prostate cancer. The mean age was 61 (range 46–79) years, with mean prostate-specific antigen of 6.7 (0.91–26.8) ng/mL at diagnosis. Of 166 patients, 117 (70.5%) patients were enrolled into the active surveillance program with 82 (70%) meeting Prostate Cancer Research International Active Surveillance (PRIAS) criteria, 44 patients underwent immediate definitive treatment (88.6% radical prostatectomy and 9.1% radiotherapy) and five watchful waiting. With a median follow-up of 1.8 years, 37 (31.6%) patients on AS had definitive treatment [30 cases (81%) were attributable to disease progression, 4 cases (10.8%) to an abnormal magnetic resonance imaging result and 3 cases (8.1%) for patient preference]. In the 35 patients who underwent radical prostatectomy immediately after diagnosis, the GS was ≥7 in 29 cases (82.9%), and the final pathology was pT3a in 16 (51.6%) and pT3b in one (2.9%). In patients who underwent radical prostatectomy after being on AS, the proportion of GS ≥7 prostate cancer was 29/32 (90.6%), with pT3a in six (18.8%) and pT3b in three (9.4%) cases. Overall, 23.5% of patients had a multiparametric magnetic resonance imaging scan. Conclusion: This single-surgeon cohort of GS 6 prostate cancer patients demonstrates a high proportion of cases managed with active surveillance, with comparable rates to international literature. The majority of cases who underwent immediate definitive treatment had significant disease, indicating that patients are being appropriately selected for active surveillance.http://www.sciencedirect.com/science/article/pii/S228788821730020XProstate cancerGleason 6Active surveillance
spellingShingle Brayden March
George Koufogiannis
Mark Louie-Johnsun
Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
Prostate International
Prostate cancer
Gleason 6
Active surveillance
title Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
title_full Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
title_fullStr Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
title_full_unstemmed Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
title_short Management and outcomes of Gleason six prostate cancer detected on needle biopsy: A single-surgeon experience over 6 years
title_sort management and outcomes of gleason six prostate cancer detected on needle biopsy a single surgeon experience over 6 years
topic Prostate cancer
Gleason 6
Active surveillance
url http://www.sciencedirect.com/science/article/pii/S228788821730020X
work_keys_str_mv AT braydenmarch managementandoutcomesofgleasonsixprostatecancerdetectedonneedlebiopsyasinglesurgeonexperienceover6years
AT georgekoufogiannis managementandoutcomesofgleasonsixprostatecancerdetectedonneedlebiopsyasinglesurgeonexperienceover6years
AT marklouiejohnsun managementandoutcomesofgleasonsixprostatecancerdetectedonneedlebiopsyasinglesurgeonexperienceover6years